{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 122 of 122', 'Appendix 7: Study Schedule of Activities for Subjects Who Discontinue Treatment Early or Exit With Ongoing Adverse', 'Event: Safety Follow-Up', 'Activity', 'Safety Follow-Up', 'Comments', 'General', 'Follow-up is for ongoing adverse events until they resolve or stabilize (for at least 30 days after early', 'discontinuation or exit), or consent for follow-up is withdrawn, or the study is terminated.', 'For subject who discontinued due to GI adverse events (Section 8.5.6.2), follow-up at the study site is', 'monthly for 6 months or until chronic or recurrent GI symptoms resolve or stabilize, whichever is last.', 'Adverse events review', 'X', 'Telephone subject who does not come to the study site.', 'Symptom-directed physical', 'X', 'For subject who discontinued due to GI adverse events.', 'examination', 'Assess systems per standard of care at the study site or as clinically indicated by symptoms.', 'Telephone follow-up by medically qualified personnel may be appropriate in the absence of symptoms, at', 'the discretion of the investigator.', 'PEESS v2.0 questionnaire', 'X', 'Instruct subject who had GI adverse events of interest (Section 8.5.6.2) to complete the questionnaire at', 'early discontinuation or study exit and monthly for 6 months.', 'GI, gastrointestinal; PEESS v2.0, Pediatric Eosinophilic Esophagitis Symptom Scores version 2.0.']", "completion": ""}